Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

Mamitaro Ohtsuki; Hiroshi Kubo; Hitomi Morishima; Ryosuke Goto; Richuan Zheng; Hidemi Nakagawa

doi:10.1111/1346-8138.14504

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.14504 ◽

2018 ◽

Vol 45 (9) ◽

pp. 1053-1062 ◽

Cited By ~ 31

Author(s):

Mamitaro Ohtsuki ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Plaque Type ◽

Interleukin 23

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Interleukin 23

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Download Full-text

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Headache The Journal of Head and Face Pain ◽

10.1111/head.14138 ◽

2021 ◽

Author(s):

Takao Takeshima ◽

Fumihiko Sakai ◽

Koichi Hirata ◽

Noboru Imai ◽

Yasuhiko Matsumori ◽

...

Keyword(s):

Japanese Patients ◽

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2017-316074.63 ◽

2017 ◽

Vol 88 (5) ◽

pp. e1.63-e1 ◽

Cited By ~ 8

Author(s):

David Dodick ◽

Messoud Ashina ◽

David Kudrow ◽

Michel Lanteri-Minet ◽

Vera Osipova ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

The Journal of Dermatology ◽

10.1111/1346-8138.14294 ◽

2018 ◽

Vol 45 (5) ◽

pp. 529-539 ◽

Cited By ~ 26

Author(s):

Shigetoshi Sano ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Generalized Pustular Psoriasis ◽

Erythrodermic Psoriasis ◽

Interleukin 23

Download Full-text

Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2019.10.087 ◽

2019 ◽

Vol 221 (6) ◽

pp. 672-673 ◽

Cited By ~ 3

Author(s):

J. Schwebke ◽

B. Carter ◽

A. Waldbaum ◽

C. Price ◽

A. Castellarnau ◽

...

Keyword(s):

Bacterial Vaginosis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

PLoS ONE ◽

10.1371/journal.pone.0215491 ◽

2019 ◽

Vol 14 (4) ◽

pp. e0215491 ◽

Cited By ~ 2

Author(s):

Satoshi Motoya ◽

Kenji Watanabe ◽

Haruhiko Ogata ◽

Takanori Kanai ◽

Toshiyuki Matsui ◽

...

Keyword(s):

Ulcerative Colitis ◽

Japanese Patients ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text